Clear Street’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Clear Street’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-185,932	Closed	-$24.2K	–	665
2024 Q4	$24.2K	Hold	185,932	–	–	﹤0.01%	246
2024 Q3	$20.3K	Sell	185,932 -4,926	-3%	-$653	﹤0.01%	310
2024 Q2	$19.1K	Hold	190,858	–	–	﹤0.01%	347
2024 Q1	$28.6K	Sell	190,858 -624	-0.3%	-$95	﹤0.01%	264
2023 Q4	$28.7K	Buy	191,482 +43,576	+29%	+$7.04K	﹤0.01%	229
2023 Q3	$34K	Buy	147,906 +789	+0.5%	+$156	﹤0.01%	304
2023 Q2	$28.1K	Buy	147,117 +57,469	+64%	+$10K	﹤0.01%	529
2023 Q1	$16.1K	Buy	+89,648	New	+$13.9K	﹤0.01%	415

Clear Street's BLACR Position: Q1 2025 in Review

Clear Street sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 185,932 shares — an estimated $24.2K sold.

Clear Street first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $34K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Clear Street reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Clear Street sold 185,932 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $24.2K.
Clear Street first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Clear Street's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $34K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Clear Street's 13F filing for Q1 2025, filed 15 May 2025.